214 related articles for article (PubMed ID: 14707152)
1. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
3. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
5. Effect of estrogen and AT1 receptor blocker on neointima formation.
Liu HW; Iwai M; Takeda-Matsubara Y; Wu L; Li JM; Okumura M; Cui TX; Horiuchi M
Hypertension; 2002 Oct; 40(4):451-7; discussion 448-50. PubMed ID: 12364346
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Takahashi H; Tomino Y
Kidney Blood Press Res; 2009; 32(4):239-49. PubMed ID: 19752573
[TBL] [Abstract][Full Text] [Related]
7. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Li JM; Iwai M; Cui TX; Min LJ; Tsuda M; Iwanami J; Suzuki J; Mogi M; Horiuchi M
Mol Pharmacol; 2005 May; 67(5):1666-73. PubMed ID: 15695623
[TBL] [Abstract][Full Text] [Related]
8. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
Inaba S; Iwai M; Tomono Y; Senba I; Furuno M; Kanno H; Okayama H; Mogi M; Higaki J; Horiuchi M
Am J Hypertens; 2009 Feb; 22(2):145-50. PubMed ID: 19057515
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
[TBL] [Abstract][Full Text] [Related]
11. Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
Rafiq K; Nishiyama A; Konishi Y; Morikawa T; Kitabayashi C; Kohno M; Masaki T; Mori H; Kobori H; Imanishi M
PLoS One; 2014; 9(9):e107853. PubMed ID: 25233358
[TBL] [Abstract][Full Text] [Related]
12. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.
Li Z; Chen XD; Ni SK; Li JW; Lin MS
Chin J Traumatol; 2004 Feb; 7(1):56-61. PubMed ID: 14728822
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
[TBL] [Abstract][Full Text] [Related]
15. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
Omote Y; Deguchi K; Kono S; Liu W; Kurata T; Hishikawa N; Yamashita T; Ikeda Y; Abe K
J Neurosci Res; 2014 Oct; 92(10):1330-7. PubMed ID: 24839960
[TBL] [Abstract][Full Text] [Related]
16. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
17. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
[TBL] [Abstract][Full Text] [Related]
18. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Kim-Mitsuyama S; Izumi Y; Izumiya Y; Yoshida K; Yoshiyama M; Iwao H
Hypertens Res; 2004 Oct; 27(10):771-9. PubMed ID: 15785013
[TBL] [Abstract][Full Text] [Related]
19. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
Bahrudin U; Ikeda N; Utami SB; Maharani N; Morikawa K; Li P; Sobirin MA; Hasegawa A; Sakata S; Endo R; Rifqi S; Shirayoshi Y; Yamamoto K; Ninomiya H; Hisatome I
Drug Res (Stuttg); 2013 Oct; 63(10):515-20. PubMed ID: 23740383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
